Restricted accessResearch articleFirst published online 2016-07
Transgene Reactivation in Induced Pluripotent Stem Cell Derivatives and Reversion to Pluripotency of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells
Induced pluripotent stem cells (iPSCs) have enormous potential in regenerative medicine and disease modeling. It is now felt that clinical trials should be performed with iPSCs derived with nonintegrative constructs. Numerous studies, however, including those describing disease models, are still being published using cells derived from iPSCs generated with integrative constructs. Our experimental work presents the first evidence of spontaneous transgene reactivation in vitro in several cellular types. Our results show that the transgenes were predominantly silent in parent iPSCs, but in mesenchymal and endothelial iPSC derivatives, the transgenes experienced random upregulation of Nanog and c-Myc. Additionally, we provide evidence of spontaneous secondary reprogramming and reversion to pluripotency in mesenchymal stem cells derived from iPSCs. These findings strongly suggest that the studies, which use cellular products derived from iPSCs generated with retro- or lentiviruses, should be evaluated with consideration of the possibility of transgene reactivation. The in vitro model described here provides insight into the earliest events of culture transformation and suggests the hypothesis that reversion to pluripotency may be responsible for the development of tumors in cell replacement experiments. The main goal of this work, however, is to communicate the possibility of transgene reactivation in retro- or lenti-iPSC derivatives and the associated loss of cellular fidelity in vitro, which may impact the outcomes of disease modeling and related experimentation.
TakahashiK and YamanakaS. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126:663–676.
7.
WernigM, MeissnerA, ForemanR, BrambrinkT, KuM, HochedlingerK, BernsteinBE and JaenischR. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature, 448:318–324.
8.
OkitaK, IchisakaT and YamanakaS. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448:313–317.
WestFD, UhlEW, LiuY, StoweH, LuY, YuP, Gallegos-CardenasA, PrattSL and SticeSL. (2011). Brief report: chimeric pigs produced from induced pluripotent stem cells demonstrate germline transmission and no evidence of tumor formation in young pigs. Stem Cells, 29:1640–1643.
11.
NakagawaM, KoyanagiM, TanabeK, TakahashiK, IchisakaT, AoiT, OkitaK, MochidukiY, TakizawaN and YamanakaS. (2008). Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol, 26:101–106.
12.
NoriS, OkadaY, NishimuraS, SasakiT, ItakuraG, KobayashiY, Renault-MiharaF, ShimizuA, KoyaI, et al. (2015). Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. Stem Cell Reports, 4:360–373.
13.
PfaffN, LachmannN, AckermannM, KohlscheenS, BrendelC, MaetzigT, NiemannH, AntoniouMN, GrezM, et al. (2013). A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells, 31:488–499.
14.
EllisJ. (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther, 16:1241–1246.
15.
IrionS, LucheH, GadueP, FehlingHJ, KennedyM and KellerG. (2007). Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol, 25:1477–1482.
16.
BoydNL, RobbinsKR, DharaSK, WestFD and SticeSL. (2009). Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells. Tissue Eng Part A, 15:1897–1907.
17.
VodyanikMA, YuJ, ZhangX, TianS, StewartR, ThomsonJA and IISlukvin. (2010). A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell, 7:718–729.
18.
KimbrelEA, KourisNA, YavanianGJ, ChuJ, QinY, ChanA, SinghRP, McCurdyD, GordonL, LevinsonRD and LanzaR. (2014). Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev, 23:1611–1624.
19.
SlukvinII and VodyanikM. (2011). Endothelial origin of mesenchymal stem cells. Cell Cycle, 10:1370–1373.
20.
MalchenkoS, XieJ, de Fatima BonaldoM, VaninEF, BhattacharyyaBJ, BelmadaniA, XiG, GalatV, GoossensW, et al. (2014). Onset of rosette formation during spontaneous neural differentiation of hESC and hiPSC colonies. Gene, 534:400–407.
21.
GalatV, MalchenkoS, GalatY, IshkinA, NikolskyY, KosakST, SoaresBM, IannacconeP, CrispinoJD and HendrixMJ. (2012). A model of early human embryonic stem cell differentiation reveals inter- and intracellular changes on transition to squamous epithelium. Stem Cells Dev, 21:1250–1263.
22.
SimpsonDL, WehmanB, GalatY, SharmaS, MishraR, GalatV and KaushalS. (2014). Engineering patient-specific valves using stem cells generated from skin biopsy specimens. Ann Thorac Surg, 98:947–954.
23.
PappB and PlathK. (2013). Epigenetics of reprogramming to induced pluripotency. Cell, 152:1324–1343.
24.
DavidL and PoloJM. (2014). Phases of reprogramming. Stem Cell Res, 12:754–761.
25.
GuillotPV, GotherstromC, ChanJ, KurataH and FiskNM. (2007). Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells, 25:646–654.
26.
PierantozziE, GavaB, ManiniI, RovielloF, MarottaG, ChiavarelliM and SorrentinoV. (2011). Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. Stem Cells Dev, 20:915–923.
27.
LiLB, ChangKH, WangPR, HirataRK, PapayannopoulouT and RussellDW. (2012). Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell, 11:615–619.
28.
ParkIH, ZhaoR, WestJA, YabuuchiA, HuoH, InceTA, LerouPH, LenschMW and DaleyGQ. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451:141–146.
NakanoK, WatanabeM, MatsunariH, MatsudaT, HondaK, MaeharaM, KanaiT, HayashidaG, KobayashiM, et al. (2013). Generating porcine chimeras using inner cell mass cells and parthenogenetic preimplantation embryos. PLoS One, 8:e61900.
31.
MontserratN, BahimaEG, BatlleL, HafnerS, RodriguesAM, GonzalezF and Izpisua BelmonteJC. (2011). Generation of pig iPS cells: a model for cell therapy. J Cardiovasc Transl Res, 4:121–130.
32.
SumerH, LiuJ, Malaver-OrtegaLF, LimML, KhodadadiK and VermaPJ. (2011). NANOG is a key factor for induction of pluripotency in bovine adult fibroblasts. J Anim Sci, 89:2708–2716.
33.
KohS and PiedrahitaJA. (2014). From “ES-like” cells to induced pluripotent stem cells: a historical perspective in domestic animals. Theriogenology, 81:103–111.
34.
PolancoJC, HoMS, WangB, ZhouQ, WolvetangE, MasonE, WellsCA, KolleG, GrimmondSM, et al. (2013). Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency. Stem Cells, 31:1498–1510.
35.
SinghR, KuaiD, GuziewiczKE, MeyerJ, WilsonM, LuJ, SmithM, ClarkE, VerhoevenA, AguirreGD and GammDM. (2015). Pharmacological modulation of photoreceptor outer segment degradation in a human iPS cell model of inherited macular degeneration. Mol Ther, 23:1700–1711.
36.
ShojiE, SakuraiH, NishinoT, NakahataT, HeikeT, AwayaT, FujiiN, ManabeY, MatsuoM and Sehara-FujisawaA. (2015). Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci Rep, 5:12831.
37.
FujiwaraN, ShimizuJ, TakaiK, ArimitsuN, UedaY, WakisakaS, SuzukiT and SuzukiN. (2015). Cellular and molecular mechanisms of the restoration of human APP transgenic mouse cognitive dysfunction after transplant of human iPS cell-derived neural cells. Exp Neurol, 271:423–431.
38.
HossiniAM, MeggesM, PrigioneA, LichtnerB, ToliatMR, WruckW, SchroterF, NuernbergP, KrollH, et al. (2015). Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene regulatory networks. BMC Genomics, 16:84.
39.
HanF, WangW, ChenB, ChenC, LiS, LuX, DuanJ, ZhangY, ZhangYA, GuoW and LiG. (2015). Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease. Cytotherapy, 17:665–679.
40.
DjuricU, CheungAY, ZhangW, MokRS, LaiW, PieknaA, HendryJA, RossPJ, PasceriP, et al., (2015). MECP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient iPS cells. Neurobiol Dis, 76:37–45.
41.
EidJE and GarciaCB. (2015). Reprogramming of mesenchymal stem cells by oncogenes. Semin Cancer Biol, 32:18–31.
42.
BuganimY, MarkoulakiS, van WietmarschenN, HokeH, WuT, GanzK, Akhtar-ZaidiB, HeY, AbrahamBJ, et al., (2014). The developmental potential of iPSCs is greatly influenced by reprogramming factor selection. Cell Stem Cell, 15:295–309.
43.
YuJ, VodyanikMA, Smuga-OttoK, Antosiewicz-BourgetJ, FraneJL, TianS, NieJ, JonsdottirGA, RuottiV, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318:1917–1920.
44.
GaoY and GaoS. (2014). Quality control: H2A.X links to better iPSCs. Cell Stem Cell, 15:259–260.
45.
KlawitterS, FuchsNV, UptonKR, Munoz-LopezM, ShuklaR, WangJ, Garcia-CanadasM, Lopez-RuizC, GerhardtDJ, et al. (2016). Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells. Nat Commun, 7:10286.
FriedliM, TurelliP, KapopoulouA, RauwelB, Castro-DiazN, RoweHM, EccoG, UnzuC, PlanetE, et al. (2014). Loss of transcriptional control over endogenous retroelements during reprogramming to pluripotency. Genome Res, 24:1251–1259.
48.
MalchenkoS, GalatV, SeftorEA, VaninEF, CostaFF, SeftorRE, SoaresMB and HendrixMJ. (2010). Cancer hallmarks in induced pluripotent cells: new insights. J Cell Physiol, 225:390–393.
49.
LaurentLC, UlitskyI, SlavinI, TranH, SchorkA, MoreyR, LynchC, HarnessJV, LeeS, et al. (2011). Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell, 8:106–118.
50.
ListerR, PelizzolaM, KidaYS, HawkinsRD, NeryJR, HonG, Antosiewicz-BourgetJ, O'MalleyR, CastanonR, et al. (2011). Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature, 471:68–73.
51.
HusseinSM, BatadaNN, VuoristoS, ChingRW, AutioR, NarvaE, NgS, SourourM, HamalainenR, et al. (2011). Copy number variation and selection during reprogramming to pluripotency. Nature, 471:58–62.
52.
GhoshZ, HuangM, HuS, WilsonKD, DeyD and WuJC. (2011). Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res, 71:5030–5039.
53.
NazorKL, AltunG, LynchC, TranH, HarnessJV, SlavinI, GaritaonandiaI, MullerFJ, WangYC, et al. (2012). Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell, 10:620–634.
54.
MaH, MoreyR, O'NeilRC, HeY, DaughtryB, SchultzMD, HariharanM, NeryJR, CastanonR, et al. (2014). Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature, 511:177–183.
55.
AmpsK, AndrewsPW, AnyfantisG, ArmstrongL, AveryS, BaharvandH, BakerJ, BakerD, MunozMB, et al. (2011). Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol, 29:1132–1144.
56.
TatenoH, OnumaY, ItoY, MinoshimaF, SaitoS, ShimizuM, AikiY, AsashimaM and HirabayashiJ. (2015). Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Reports, 4:811–820.
57.
WylesSP, YamadaS, OommenS, MaleszewskiJJ, BeraldiR, Martinez-FernandezA, TerzicA and NelsonTJ. (2014). Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy. Stem Cells Dev, 23:2274–2282.
58.
Ben-DavidU and BenvenistyN. (2014). Chemical ablation of tumor-initiating human pluripotent stem cells. Nat Protoc, 9:729–740.
59.
WuT, LiuY, WenD, TsengZ, TahmasianM, ZhongM, RafiiS, StadtfeldM, HochedlingerK and XiaoA. (2014). Histone variant H2A.X deposition pattern serves as a functional epigenetic mark for distinguishing the developmental potentials of iPSCs. Cell Stem Cell, 15:281–294.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
